Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · LISATA THERAPEUTICS, INC. (LSTA)

Lisata Completes Marea Merger and Announces $225 Million Private Placement

Mixed Impact 5 of 5 m&a Written later

Lisata Therapeutics acquired Marea Therapeutics on September 17, 2026, issuing 1,793,129 shares of common stock and 211,365.213 shares of Series C convertible preferred stock to Marea stockholders. A concurrent private placement is expected to raise about $225 million in gross proceeds, and the filing says pre-transaction Lisata stockholders will hold about 2.39% of the company's common stock after the financing, which substantially dilutes existing holders.

Key points

  • Lisata issued 1,793,129 common shares and 211,365.213 Series C preferred shares to Marea stockholders; each preferred share converts into 1,000 common shares, subject to Lisata stockholder approval
  • Concurrent private placement with a gross value of about $225 million; the investors will receive Series C preferred shares at about $1,491.37 per share
  • Post-financing ownership: pre-transaction Lisata holders about 2.39%, former Marea holders about 59.54%, private placement investors about 38.07%
  • Lisata's CEO is Dr. David J. Mazzo; Dr. Josh Lehrer was newly appointed President and Chief Operating Officer of Lisata

The filing

CompanyLISATA THERAPEUTICS, INC. (LSTA)
Form8-K, current report
Filed with the SECSep 17, 2026, 9:27 AM ET
Accession number0001140361-26-036866

Items reported: 1.01 Material Definitive Agreement2.01 Acquisition or Disposition Completed3.02 Unregistered Equity Sale5.02 Director / Officer Change5.03 Bylaw / Charter Amendment7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 17, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.